rs1799987 — CCR5 CCR5 Promoter -2459A>G

CCR5 Promoter Variant — Tuning Your Inflammatory Receptor Dial

Your immune system deploys chemokine receptors like radio antennas — they pick up distress signals from inflamed tissue and direct immune cells to the scene. CCR5 (C-C chemokine receptor 5)¹¹ CCR5 (C-C chemokine receptor 5)
a G-protein-coupled receptor expressed on T cells, monocytes, and macrophages that binds the chemokines CCL3, CCL4, and CCL5/RANTES, directing immune cell trafficking to sites of infection and inflammation sits at the intersection of infectious immunity and vascular inflammation. The rs1799987 variant, located at position −2459 in the CCR5 promoter, governs how loudly this antenna is tuned — and the consequences ripple from HIV susceptibility to atherosclerotic plaque formation.

Note: This variant is often labeled CCR5 59029 A/G or −2459G>A in the literature. The reference allele on the GRCh38 plus strand is A; the G allele is the alternate.

The Mechanism

The rs1799987 position sits within a regulatory region of the CCR5 promoter that modulates transcriptional output. In vitro reporter assays demonstrate that the G allele reduces CCR5 promoter activity by approximately 45% relative to the A allele²² 45% relative to the A allele
measured in reporter gene assays; Martinson et al. MACS, Lancet 1997. This translates to lower CCR5 mRNA production and fewer CCR5 receptors on the surface of T cells and monocytes. The A allele, by contrast, drives higher CCR5 surface density, expanding both the targets available for CCR5-tropic pathogens and the pool of monocytes equipped to respond to CCL5/RANTES gradients in inflamed vessel walls.

The variant is part of a larger CCR5 haplotype system. The most famous CCR5 variant, CCR5-Δ32 (rs333), is a 32-bp deletion that truncates the receptor; rs1799987 operates through a different mechanism — reduced expression of an otherwise intact receptor.

The Evidence

HIV and immune cell trafficking: The Multicenter AIDS Cohort Study (MACS)³³ Multicenter AIDS Cohort Study (MACS)
Martinson et al. Lancet 1997 established the foundational evidence: in a cohort of HIV-1 seroconverters lacking both CCR5-Δ32 and CCR2-64I alleles, G/G homozygotes progressed to AIDS an average of 3.8 years more slowly than A/A homozygotes (p=0.004). G/G protection was described as approximately twice that of CCR5-Δ32 in this cohort. The mechanism is straightforward: HIV R5-tropic strains use CCR5 as a co-receptor to enter CD4+ T cells; fewer surface receptors means fewer entry points.

Atherosclerosis: CCR5 and its ligands are expressed in human atherosclerotic plaque. CCR5 immunoreactivity is elevated in unstable plaque regions compared to stable regions, colocalizing with smooth muscle cells and macrophages. In ApoE-knockout mice fed a high-fat diet⁴⁴ ApoE-knockout mice fed a high-fat diet
Potteaux et al. Arterioscler Thromb Vasc Biol 2006, genetic deletion of Ccr5 (but not Ccr1) significantly reduced lesion area, macrophage content, and Th1-polarization within plaques, while increasing smooth muscle content and IL-10 expression — a more stable plaque phenotype. Critically, protection was sustained over 22 weeks of high-fat diet, arguing against a transient effect.

Human cardiovascular data are mixed. A Taiwanese case-control study (483 subjects undergoing coronary angiography) found that GG/GA carriers were more frequent among patients with acute coronary syndrome than those with stable CAD or no CAD (OR 1.853, 95% CI 1.176–2.921, p=0.008), though no significant association was seen with stable CAD — an unexpected direction given the HIV biology, possibly reflecting population-specific haplotype context or confounding by CCR5-Δ32 co-distribution. Larger genome-wide studies in European populations have not identified rs1799987 as a significant independent predictor of coronary artery disease, placing the cardiovascular evidence at the emerging-to-moderate level.

Cardiac inflammation: In chronic Chagas disease⁵⁵ chronic Chagas disease
Medeiros et al. PLOS One 2015, the AA genotype was significantly more common in patients with the cardiac form than in those with digestive-form disease or healthy controls (recessive model, p=0.036), fitting the model that higher CCR5 expression on leukocytes drives the intense myocarditis characteristic of cardiac Chagas disease.

Inflammatory disease: In Löfgren's syndrome (sarcoidosis)⁶⁶ Löfgren's syndrome (sarcoidosis)
Loke et al. Cells 2021 (106 patients, 257 controls), the G allele was more frequent in patients (OR 1.680, p=0.0015), while GG carriers showed higher CCR5 surface density on monocytes but paradoxically impaired downstream calcium signaling — suggesting that genotype-driven expression differences and functional receptor coupling are dissociable.

Practical Actions

The cardiovascular implications of rs1799987 are at the level of monocyte-driven plaque inflammation rather than a single binary risk. AA homozygotes carry the highest CCR5-driven inflammatory burden at the vascular wall, supporting stricter attention to cardiovascular risk factors that interact with the CCR5/CCL5 axis — notably obesity, smoking, and chronic infection, each of which elevates circulating CCL5/RANTES. AG heterozygotes occupy an intermediate position.

For individuals with concurrent cardiovascular risk, the CCR5 promoter genotype provides biological context: the A allele predicts a monocyte population primed for CCL5-driven tissue recruitment. This makes anti-inflammatory lifestyle measures particularly mechanistically relevant, and surveillance for subclinical atherosclerosis (carotid intima-media thickness, coronary calcium scoring) a targeted investment.

Interactions

The rs1799987 A allele acts in the same inflammatory recruitment pathway as the CCL2 promoter variant rs1024611 (MCP-1 A-2518G, also in heart-inflammation). Both variants raise the set-point of monocyte recruitment to inflamed tissue — rs1024611 via more MCP-1 ligand; rs1799987 via more CCR5 receptor. Individuals carrying risk alleles at both loci may experience amplified monocyte trafficking to atherosclerotic plaques, though no direct compound study has been published for this specific combination.

CCR5-Δ32 (rs333), the 32-bp deletion that eliminates surface CCR5 expression almost entirely, is a distinct and stronger variant: Δ32 homozygotes lack functional CCR5 and are virtually immune to CCR5-tropic HIV. Heterozygous Δ32 carriers have approximately 50% fewer surface receptors than wild-type. The rs1799987 G allele operates through the same direction (reduced expression) but with a more modest ~45% reduction in transcription versus Δ32's near-complete loss of function.